Discontinuing tyrosine kinase inhibitor maintenance after extended complete molecular response should only be attempted as part of a clinical trial, the researchers say.

B-cell acute lymphoblastic leukemia (B-ALL) is a life-threatening and highly aggressive form of blood cancer. It is the most ...

Two scientists describe how an acute myeloid leukemia diagnosis underscores the need for continued federal support for research and access to care.

Treatment of B-cell Acute Lymphoblastic Leukaemia has improved thanks to CAR-T therapies, but relapse is still very common.

B-cell Acute Lymphoblastic Leukemia (B-ALL) is a life-threatening and highly aggressive form of blood cancer. It is the most ...

Therapy-related B-cell acute lymphoblastic leukemia (B-ALL), a rare form of acute lymphoblastic leukemia (ALL), may develop in patients receiving cytotoxic treatments for a prior malignancy, according ...

Zavier Sexton, Graham Smith, Bryce Miller and Natalie Vulhop were honored as young heroes at the 2025 CBJ Foundation ...

12, 2024 — Scientists have identified novel genetic variations that influence relapse risk in children with standard risk B-cell acute lymphoblastic leukemia (SR B-ALL), the most common childhood ...

The study builds on a small body of previous research, but Colorado’s oil and gas industry strongly disputes the findings.

Tanda leukemia kadang samar dan mungkin mirip dengan gejala penyakit lain. Apa saja gejala leukemia pada anak? Berikut ...

Aptevo Therapeutics (NASDAQ:APVO) announced two additional frontline Acute Myeloid Leukemia (AML) patients have achieved ...

Pacylex Pharmaceuticals Inc. (Pacylex) is a clinical-stage pharmaceutical company and world leader in developing ...